<?xml version="1.0" encoding="US-ASCII" ?>
<rss version="2.0">
<channel>
	<title>FDA Webview</title>
	<description>The leading publisher of FDA News, FDA Review, FDA Compliance, QSR News, and Food Drug Administration information since 1984.</description>
	<link>http://fdaweb.com/</link>
	<lastBuildDate>Fri, 17 Jul 2026 21:49:48 -0500</lastBuildDate>
	<item>
		<title>Friendly Accelerated Approval Disclosures Improve Drug Understanding: Study </title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161477</link>
		<description>A new study suggests that direct-to-consumer prescription drug Web sites may better communicate the limitations of FDA accelerated approvals when disclosures use consumer-friendly language rather than technical wording drawn from physician labeling.</description>
		<pubDate>Fri, 17 Jul 2026 10:51:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161477</guid>
	</item>
	<item>
		<title>Class I Recall of Bolton Medical’s Relay Pro Thoracic Stent Graft System</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161476</link>
		<description>Bolton Medical recalls its Relay Pro Thoracic Stent Graft Systems due to reports of a deployment failure that may result in serious injury or death.</description>
		<pubDate>Fri, 17 Jul 2026 10:33:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161476</guid>
	</item>
	<item>
		<title>FDA Cites Charles River Endosafe Lab Over Quality System Deficiencies </title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161475</link>
		<description>FDA issues a Form-483 to Charles River Laboratories&#039; Endosafe contract testing laboratory in Charleston, SC, over multiple quality system deficiencies following a March inspection.</description>
		<pubDate>Fri, 17 Jul 2026 08:29:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161475</guid>
	</item>
	<item>
		<title>Camurus NDA Resubmission for Acromegaly Therapy Accepted by FDA</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161474</link>
		<description>FDA accepts for review a Camurus NDA resubmission for Oclaiz (octreotide), a long-acting injection for treating acromegaly.</description>
		<pubDate>Fri, 17 Jul 2026 07:47:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161474</guid>
	</item>
	<item>
		<title>Fujifilm Diosynth Cited Over NC Plant’s Microbial Contamination Controls</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161473</link>
		<description>FDA cites Fujifilm Diosynth Biotechnologies USA for significant manufacturing deficiencies at its drug substance facility in Research Triangle Park, NC.</description>
		<pubDate>Fri, 17 Jul 2026 06:22:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161473</guid>
	</item>
	<item>
		<title>Kalshi Launches Prediction Markets for Clinical Trial, FDA Outcomes</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161472</link>
		<description>Kalshi launches a pilot program allowing traders to buy and sell contracts tied to the outcomes of late-stage clinical trials and FDA regulatory decisions.</description>
		<pubDate>Thu, 16 Jul 2026 11:14:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161472</guid>
	</item>
	<item>
		<title>FDA OKs Merck&#039;s Oral PCSK9 Inhibitor for Lowering Cholesterol</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161471</link>
		<description>FDA approves Merck&#039;s Lipfendra (enlicitide) 20 mg tablets as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol in certain adults with hypercholesterolemia.</description>
		<pubDate>Thu, 16 Jul 2026 11:07:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161471</guid>
	</item>
	<item>
		<title>CDER Planning 85 New, Revised Guidances</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161470</link>
		<description>FDA publishes the latest CDER guidance agenda showing plans for 85 new or revised guidances to be issued in 2026.</description>
		<pubDate>Thu, 16 Jul 2026 10:58:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161470</guid>
	</item>
	<item>
		<title>FDA Reevaluating Makary’s Journal Articles, Podium Policies: DeGette </title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161469</link>
		<description>Rep. Diana DeGette (D-CO) wins FDA assurances that several policy announcements issued during former commissioner Marty Makary&#039;s tenure — including articles published in medical journals and media interviews— are not intended to be recognized as official agency guidance.</description>
		<pubDate>Thu, 16 Jul 2026 10:47:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161469</guid>
	</item>
	<item>
		<title>Active Drug Shortages Still Trending Up</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161468</link>
		<description>The American Society of Health System Pharmacists says there were 227 active drug shortages in the second quarter of 2026, trending up for the third quarter in a row. </description>
		<pubDate>Thu, 16 Jul 2026 10:33:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161468</guid>
	</item>
	<item>
		<title>Court Backs FDA, Medtronic in Stimulator Suits</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161467</link>
		<description>MassDevice reports a Minnesota federal judge gave significant victories to Medtronic and FDA in four cases involving the company’s spinal cord stimulators. </description>
		<pubDate>Thu, 16 Jul 2026 10:17:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161467</guid>
	</item>
	<item>
		<title>13 Observations in Zhejiang Hushai Inspection</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161466</link>
		<description>FDA releases the form FDA-483 with 13 observations from an April inspection at China’s Zhejiang Hushai Pharmaceutical Co.</description>
		<pubDate>Thu, 16 Jul 2026 08:43:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161466</guid>
	</item>
	<item>
		<title>Alvotech EF FDA-483 Released</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161465</link>
		<description>FDA releases the form FDA-483 with five observations from an inspection at Iceland’s Alvotech EF.</description>
		<pubDate>Thu, 16 Jul 2026 08:40:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161465</guid>
	</item>
	<item>
		<title>Axsome NDA for Cataplexy in Patients with Narcolepsy </title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161464</link>
		<description>FDA accepts for review an Axsome Therapeutics NDA for AXS-12 (reboxetine) for treating cataplexy in patients with narcolepsy.</description>
		<pubDate>Wed, 15 Jul 2026 13:37:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161464</guid>
	</item>
	<item>
		<title>Priority Review for Gazyva sBLA for Primary Membranous Nephropathy</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161463</link>
		<description>

FDA grants Roche a priority review for its supplemental BLA seeking approval for Gazyva (obinutuzumab) for treating adults with primary membranous nephropathy.</description>
		<pubDate>Wed, 15 Jul 2026 11:12:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161463</guid>
	</item>
	<item>
		<title>Kennedy Wanted Sentinel, BEST Data: Reuters</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161462</link>
		<description>A Reuters deep dive into HHS secretary Robert F. Kennedy Jr.’s efforts to eliminate childhood vaccine requirements says his aides asked FDA for access to Sentinel and BEST data.</description>
		<pubDate>Wed, 15 Jul 2026 10:48:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161462</guid>
	</item>
	<item>
		<title>VAI Close Out for HLB Inspection</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161461</link>
		<description>A Cancer Network post says FDA issued a voluntary action indicated close-out letter to HLB following a CGMP inspection at a facility manufacturing the company’s hepatocellular cancer drug.</description>
		<pubDate>Wed, 15 Jul 2026 10:03:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161461</guid>
	</item>
	<item>
		<title>A ‘New Era of Innovation’ for FDA Public Health Pillars</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161460</link>
		<description>FDA acting commissioner Kyle Diamantas positions the agency’s four public health pillars as a means to fulfill its enduring mission in a new era.</description>
		<pubDate>Wed, 15 Jul 2026 09:59:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161460</guid>
	</item>
	<item>
		<title>House Hearing Previews Debate Over FDA Modernization, User Fees</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161459</link>
		<description>House Energy and Commerce Health Subcommittee leaders reveal differing views over whether the Trump administration&#039;s policies are strengthening or undermining the nation&#039;s drug development enterprise.</description>
		<pubDate>Wed, 15 Jul 2026 09:50:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161459</guid>
	</item>
	<item>
		<title>Hearing Highlights Concerns Over Biomedical Innovation Growing in China</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161458</link>
		<description>Witnesses at a House Energy and Commerce Health Subcommittee hearing urge lawmakers to modernize the nation&#039;s clinical trial system, and strengthen FDA’s scientific capacity to offset China’s rapidly growing share of early-stage drug development.</description>
		<pubDate>Wed, 15 Jul 2026 09:47:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161458</guid>
	</item>
</channel>
</rss>